Clinical Scorecard: FDA Broadens Pitolisant Label
At a Glance
| Category | Detail |
|---|---|
| Condition | Narcolepsy with or without cataplexy |
| Key Mechanisms | Selective histamine 3 receptor antagonist and inverse agonist, believed to increase histamine synthesis and release. |
| Target Population | Pediatric and adult patients aged 6 years and older |
| Care Setting | Outpatient clinical settings |
Key Highlights
- Only non-scheduled therapy approved for narcolepsy in the US.
- Indicated for excessive daytime sleepiness and cataplexy.
- Approved for pediatric patients aged 6 years and older.
- Received orphan drug designation in 2010 and breakthrough therapy designation in 2018.
- Narcolepsy affects approximately 170,000 people in the US.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of narcolepsy based on clinical criteria including excessive daytime sleepiness and cataplexy.
Management
- Pitolisant can be prescribed for managing excessive daytime sleepiness and cataplexy.
Monitoring & Follow-up
- Monitor for QT prolongation and adverse reactions such as insomnia, nausea, and anxiety.
Risks
- Contraindicated in patients with hypersensitivity to pitolisant or severe hepatic impairment.
Patient & Prescribing Data
Patients with narcolepsy aged 6 years and older.
Efficacy believed to be mediated through histamine 3 receptor activity.
Clinical Best Practices
- Assess for history of cardiac arrhythmias before prescribing.
- Educate patients about potential side effects including insomnia and anxiety.
- Consider alternative therapies for patients with known QT prolongation.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
